Heartwood Wealth Advisors LLC, a prominent investment advisory firm, has recently announced a significant boost in its position in shares of Johnson & Johnson (NYSE:JNJ). According to the company’s most recent disclosure with the Securities and Exchange Commission (SEC), Heartwood Wealth Advisors increased its position in the pharmaceutical giant by an impressive 41.1% during the first quarter of this year. This move reflects the confidence and optimism that Heartwood holds for Johnson & Johnson’s future prospects.
As of its most recent filing with the SEC, Heartwood Wealth Advisors now owns 4,304 shares of Johnson & Johnson stock, representing an additional acquisition of 1,254 shares during the first quarter. The total value of Heartwood’s holdings in Johnson & Johnson currently stands at approximately $667,000. This substantial increase in both shareholdings and overall investment underscores Heartwood’s faith in the company’s ability to generate solid returns for its investors.
In addition to boosting their position, Heartwood Wealth Advisors highlights another positive development for investors – news about a recently disclosed quarterly dividend by Johnson & Johnson. On June 6th, shareholders who were on record as of May 23rd received a dividend payment amounting to $1.19 per share. Annually, this represents a dividend payout of $4.76 per share and yields at around 2.92%. It is important to note that this dividend incrementally surpasses the previous figure of $1.13 per share.
This announcement serves as reassuring news for investors seeking stable income through dividends from their investments in well-established companies such as Johnson & Johnson. The decision to raise dividend payouts demonstrates management’s commitment to rewarding shareholders while maintaining financial stability and continued growth.
Parallelly, it was reported that one of Johnson & Jonson’s executive vice presidents, Kathryn E. Wengel, sold 12,465 shares of the company’s stock on June 12th. The shares were sold at an average price of $160.00, resulting in a total value of approximately $1,994,400.00. Following the sale, Wengel holds 65,934 shares directly in the company, valued at around $10,549,440. This move by the executive vice president demonstrates her confidence in Johnson & Johnson’s market performance and her belief that it will continue to grow.
It is also worth mentioning that corporate insiders currently possess 0.20% of the Johnson & Johnson stock. Insider ownership like this can instill further confidence in potential investors as those who have intimate knowledge of the company’s operations believe in its success and future prospects.
As a highly respected investment advisory firm that is well-versed in financial markets and has extensive experience with managing diverse portfolios, Heartwood Wealth Advisors’ increased position in Johnson & Johnson undoubtedly reflects strong factors underpinning the pharmaceutical giant’s growth potential. With a significant boost to their holdings as well as positive news regarding increased dividend payouts and insider trades, Heartwood Wealth Advisors appears poised for continued success with their investment strategy focused on Johnson & Johnson.
Investors should take note of Heartwood Wealth Advisors’ maneuvering and explore potential opportunities presented by this investment advisory firm’s action. As always though, it is important for investors to conduct thorough research and analysis before making any investment decisions based on these recent developments within Johnson & Johnson or other companies they may be considering for their portfolio.
Overall, this news demonstrates the inherent strength of a reputable company like Johnson & Johnson and serves as a testament to its ability to provide attractive investment opportunities for both mainstream investors and sophisticated financial firms alike.
[bs_slider_forecast ticker=”JNJ”]
Institutional Investors and Research Firms Express Confidence in Johnson & Johnson’s Performance
Johnson & Johnson, a renowned pharmaceutical and consumer goods company, has recently seen significant activity from institutional investors. Vanguard Group Inc., for instance, increased its holdings in the company by 1.2% during the third quarter, acquiring an additional 2,815,655 shares. State Street Corp and Moneta Group Investment Advisors LLC also boosted their positions in Johnson & Johnson during the same period.
Geode Capital Management LLC increased its holdings by 0.6% in the fourth quarter while Morgan Stanley saw a 12.0% increase in their holdings of the company’s stock during that period as well. These activities highlight the interest and confidence that institutional investors have in Johnson & Johnson.
Research firms have also weighed in on JNJ’s performance recently. UBS Group gave a “neutral” rating with a price target of $164.00 for the company. StockNews.com labeled it as a “strong buy,” while Citigroup issued a “buy” rating with a price target of $185.00 for the stock. Analysts at Atlantic Securities and Raymond James gave neutral and outperform ratings respectively.
The positive reception from both institutional investors and research firms can be attributed to several factors, including Johnson & Johnson’s recent disclosure of quarterly dividends. Shareholders who were recorded on May 23rd received a dividend of $1.19 per share, an increase from the previous payout of $1.13 per share.
The increase in dividend payout reflects the company’s financial strength and commitment towards rewarding its shareholders. Furthermore, it enhances investor sentiment amidst market volatility.
Johnson & Johnson opened at $162.97 on Thursday with key financial indicators suggesting stability and growth potential for investors to stay confident about its prospects despite short-term fluctuations in stock prices.
With a market capitalization of $423.52 billion, Johnson & Johnson is listed on New York Stock Exchange (NYSE: JNJ) – Free Report.
The company’s debt-to-equity ratio of 0.49 signifies a conservative capital structure. Additionally, the current and quick ratios of 1.07 and 0.85 respectively portray strong liquidity positions.
Moving averages indicate the stock price’s stability with a 50-day simple moving average of $160.72, well above the 52-week low of $150.11 and slightly lower than its yearly high of $181.04.
Johnson & Johnson’s recent quarterly earnings report also showcased positive results, with earnings per share (EPS) of $2.68 surpassing analysts’ consensus estimates by $0.17. The firm’s revenue for that quarter was $24.75 billion, beating the estimated figure by over a billion dollars.
With a net margin at an impressive 13.22% and a return on equity of 36.13%, Johnson & Johnson exhibits a solid financial performance backed by successful products in both pharmaceuticals and consumer goods sectors.
Industry insiders expect that Johnson & Johnson will continue to deliver strong financial results moving forward, projecting earnings per share of 10.66 for the current year.
In conclusion, institutional investors have shown confidence through increased holdings in Johnson & Johnson, while research firms have provided positive reviews and ratings for the company’s performance.
Moreover, the increase in dividend payout reflects its commitment towards shareholders.
With stable financial indicators and successful products that drive revenue growth, Johnson & Johnson is primed for continued success in their industry as they strive to improve healthcare worldwide.